Blood Based Biomarkers Market Expands with Advances in Precision Medicine and Liquid Biopsy Research

The Global Blood Based Biomarkers Market reached US$ 10.78 billion in 2025 and is expected to reach US$ 41.43 billion by 2035, growing with a CAGR of 14.2% during the forecast period 2026-2035. Growth is driven by increasing demand for minimally invasive diagnostic techniques and precision medicine. Rising prevalence of cancer, cardiovascular, and neurological disorders is accelerating biomarker adoption. The growing emphasis on early disease detection and personalized treatment is further supporting market expansion. Additionally, advancements in molecular diagnostics and biomarker discovery technologies are improving clinical accuracy. Expanding investments in clinical research and companion diagnostics are also contributing to strong market growth.

Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/blood-based-biomarkers-market?prasad

United States: Recent Developments

✅ In June 2026, Quest Diagnostics expanded its blood-based biomarker testing portfolio with advanced assays supporting early detection of neurodegenerative and oncology conditions. The development improves precision diagnostics. Quest Diagnostics continues advancing laboratory medicine.

✅ In May 2026, Labcorp enhanced its biomarker testing capabilities with AI-supported blood-based diagnostic solutions for personalized healthcare. The innovation improves clinical decision-making. Labcorp continues strengthening precision medicine services.

✅ In April 2026, Exact Sciences expanded development of blood-based biomarker technologies for multi-cancer detection and early disease screening. The development strengthens non-invasive diagnostics. Exact Sciences continues advancing molecular testing.

✅ In April 2026, Guardant Health improved its liquid biopsy platform with enhanced blood-based biomarker analysis for precision oncology applications. The innovation supports personalized cancer treatment. Guardant Health continues advancing cancer diagnostics.

Japan: Recent Developments

✅ In June 2026, Sysmex Corporation expanded its blood-based biomarker portfolio with advanced molecular diagnostic technologies for oncology and inflammatory diseases. The development improves clinical testing accuracy. Sysmex continues advancing precision diagnostics.

✅ In May 2026, Fujirebio enhanced its blood-based biomarker assays for neurodegenerative disease diagnosis with improved analytical sensitivity. The innovation supports earlier disease detection. Fujirebio continues strengthening in-vitro diagnostics.

✅ In April 2026, Shimadzu Corporation improved biomarker analysis platforms with advanced mass spectrometry technologies for clinical research. The development enhances diagnostic precision. Shimadzu continues advancing analytical instrumentation.

✅ In April 2026, Canon Medical Systems strengthened its precision diagnostics portfolio by integrating blood-based biomarker analytics with advanced clinical imaging workflows. The innovation supports comprehensive disease assessment. Canon Medical continues expanding diagnostic solutions.

Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=blood-based-biomarkers-market?prasad

Blood Based Biomarkers Market Major Players:

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche is a global leader in the blood-based biomarkers market, leveraging its expertise in in vitro diagnostics, molecular diagnostics, and precision medicine. In 2025, the company reported revenue of USD 72.0 billion, driven by pharmaceuticals and diagnostics. In the blood-based biomarkers market, Roche plays a major role by developing advanced immunoassays, molecular diagnostic platforms, and companion diagnostics that enable the early detection, monitoring, and personalized treatment of cancer, neurological disorders, cardiovascular diseases, and other chronic conditions through minimally invasive blood testing.

Abbott Laboratories

Abbott is a leading provider of diagnostic technologies and a key participant in the blood-based biomarkers market. In 2025, the company reported revenue of USD 42.0 billion, driven by diagnostics, medical devices, nutrition, and established pharmaceuticals. In the blood-based biomarkers market, Abbott plays a significant role by offering high-sensitivity immunoassay analyzers and biomarker testing solutions for cardiac diseases, oncology, infectious diseases, and neurological disorders. Its laboratory and point-of-care diagnostic platforms support rapid, accurate biomarker detection to improve clinical decision-making and patient outcomes.

Siemens Healthineers AG

Siemens Healthineers is a major innovator in the blood-based biomarkers market through its advanced laboratory diagnostics and precision medicine portfolio. In 2025, the company reported revenue of USD 24.0 billion, driven by imaging, laboratory diagnostics, and digital healthcare solutions. In the blood-based biomarkers market, Siemens Healthineers plays a key role by providing automated immunoassay systems, clinical chemistry analyzers, and biomarker testing platforms that support early disease detection, treatment monitoring, and personalized healthcare. Its solutions are widely used for biomarker analysis in oncology, cardiovascular disease, neurodegenerative disorders, and infectious disease diagnostics.

Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/blood-based-biomarkers-market?prasad

Segment Covered in the Blood Based Biomarkers Market:

By Biomarker Type: Protein Biomarkers
Protein biomarkers dominate the blood-based biomarkers market due to their widespread use in disease diagnosis, prognosis, treatment monitoring, and therapeutic response assessment. They are extensively utilized in oncology, cardiovascular diseases, neurodegenerative disorders, and infectious disease testing because of their high clinical relevance and well-established diagnostic value.
The protein biomarkers segment accounts for approximately 48% of the total market. Based on a global market size assumption of USD 18.4 billion in 2025, this translates to an estimated segment value of USD 8.83 billion. Growth is driven by increasing biomarker-based diagnostics, expanding precision medicine, and advancements in proteomics technologies.

By Disease Area: Oncology
Oncology represents the largest disease area due to the increasing adoption of blood-based biomarkers for early cancer detection, companion diagnostics, treatment selection, disease monitoring, and recurrence surveillance. Liquid biopsy technologies have further accelerated the use of blood biomarkers in cancer management.
The oncology segment accounts for approximately 42% of the total market. Based on the USD 18.4 billion global market size in 2025, this corresponds to an estimated value of USD 7.73 billion. Growth is driven by rising cancer incidence, increasing demand for non-invasive diagnostics, and growing adoption of personalized oncology therapies.

By Application: Diagnostics
Diagnostics dominate the blood-based biomarkers market as blood biomarkers are routinely used for disease detection, risk assessment, patient stratification, and clinical decision-making across multiple therapeutic areas. Their ability to provide rapid, minimally invasive diagnostic information has made them an integral part of modern healthcare.
The diagnostics segment accounts for approximately 51% of the total market. Based on the USD 18.4 billion global market size in 2025, this translates to an estimated value of USD 9.38 billion. Growth is driven by increasing adoption of precision diagnostics, expanding biomarker-based testing, and advances in molecular diagnostic technologies.

By Technology: Next-Generation Sequencing (NGS)
Next-generation sequencing (NGS) dominates the market due to its ability to simultaneously analyze multiple genetic biomarkers with high sensitivity and accuracy. NGS has become a key technology for liquid biopsy, precision oncology, and genomic medicine, enabling comprehensive biomarker profiling from blood samples.
The NGS segment accounts for approximately 37% of the total market. Based on the USD 18.4 billion global market size in 2025, this corresponds to an estimated value of USD 6.81 billion. Growth is driven by declining sequencing costs, increasing clinical adoption of genomic testing, and expanding applications in personalized medicine.

By Sample Type: Plasma
Plasma is the leading sample type due to its high concentration of circulating biomarkers, including circulating tumor DNA (ctDNA), proteins, exosomes, and cell-free nucleic acids. It is widely preferred for liquid biopsy applications because it offers reliable biomarker detection while minimizing sample degradation.
The plasma segment accounts for approximately 56% of the total market. Based on the USD 18.4 billion global market size in 2025, this translates to an estimated value of USD 10.30 billion. Growth is driven by increasing use of liquid biopsy, improvements in sample processing technologies, and growing demand for minimally invasive diagnostic testing.

By End User: Hospitals & Diagnostic Laboratories
Hospitals and diagnostic laboratories represent the largest end-user segment due to the high volume of biomarker-based testing performed for disease diagnosis, treatment monitoring, and routine clinical screening. These facilities continue to expand molecular diagnostic capabilities to support precision medicine initiatives.
The hospitals and diagnostic laboratories segment accounts for approximately 54% of the total market. Based on the USD 18.4 billion global market size in 2025, this corresponds to an estimated value of USD 9.94 billion. Growth is driven by increasing demand for molecular diagnostics, expanding clinical laboratory infrastructure, and greater adoption of biomarker-guided treatment strategies.

Market Segmentation
The Blood-Based Biomarkers Market is segmented by biomarker type into protein biomarkers, genetic biomarkers, metabolomic biomarkers, and others; by disease area into oncology, cardiovascular diseases, neurological disorders, infectious diseases, and others; by application into diagnostics, drug discovery & development, prognostics, and others; by technology into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, mass spectrometry, and others; by sample type into plasma, serum, whole blood, and others; and by end user into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academic & research institutes, and others.

Regional Analysis

North America
North America is the leading blood-based biomarkers market due to advanced molecular diagnostics infrastructure, strong pharmaceutical research, and widespread adoption of precision medicine. The region is led by the United States, where significant investments in biomarker research, liquid biopsy, and companion diagnostics continue to drive market growth.
The North American market is estimated at approximately USD 7.91 billion in 2025, accounting for about 43% of the global market. Growth is driven by increasing cancer screening programs, rising adoption of liquid biopsy technologies, and expanding investments in precision oncology.

Europe
Europe is a significant market supported by strong biomedical research, growing precision medicine initiatives, and increasing adoption of advanced diagnostic technologies. Key contributors include Germany, United Kingdom, and France.
The European market is valued at approximately USD 5.34 billion in 2025, representing about 29% of the global market. Growth is driven by expanding genomic medicine programs, increasing clinical biomarker validation, and growing demand for personalized healthcare.

Asia Pacific
Asia Pacific is the fastest-growing blood-based biomarkers market due to expanding healthcare infrastructure, rising prevalence of chronic diseases, and increasing investments in molecular diagnostics and precision medicine. Major markets include China, Japan, India, and South Korea.
The region is valued at approximately USD 5.15 billion in 2025, accounting for about 28% of the global market. Growth is driven by increasing adoption of liquid biopsy, expanding genomic research, and rising healthcare investments across emerging economies.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/blood-based-biomarkers-market?prasad

Data-Driven Research Methodology for the Blood Based Biomarkers Market:

Our research process for the Blood Based Biomarkers Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.

For More Information@ https://www.datamintelligence.com/research-report/blood-based-biomarkers-market

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.

This release was published on openPR.